Valuation: Mangalam Drugs & Organics Limited

Market Cap 51Cr 53.49L 48.09L 44.88L 40.68L 76.37L 76.84L 5.39Cr 2.1Cr 26Cr 2.01Cr 1.96Cr 85Cr P/E 2025
17.5x
P/E 2026 -0.99x
Enterprise Value 162.96Cr 1.71Cr 1.54Cr 1.44Cr 1.3Cr 2.44Cr 2.46Cr 17Cr 6.73Cr 85Cr 6.43Cr 6.29Cr 272.01Cr EV / Sales 2025
0.66x
EV / Sales 2026 0.67x
Free-Float
62.31%
Yield 2025 *
-
Yield 2026 -
17/08 Mangalam Drugs and Organics Limited Discloses Default on Bank Loan Accounts with Bank of Baroda and Bank of Maharashtra CI
13/08 Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
18/06 Mangalam Drugs and Organics Ltd. Defaults on Loan Obligations to Bank of Baroda and Bank of Maharashtra CI
14/05 Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
17/04 Mangalam Drugs & Organics Limited Announces Resignation of Anuradha Pandey as Company Secretary & Compliance Officer, Effective March 29, 2026 CI
16/04 Mangalam Drugs and Organics Limited Defaults on Loan Obligations Exceeding 30 Days with INR 95.197 Million to Bank of Maharashtra and INR 60.608 Million to Bank of Baroda CI
26/03 Mangalam Drugs and Organics Limited Appoints Shweta Patel as Company Secretary & Compliance Officer, Effective April 1, 2026 CI
17/03 Mangalam Drugs and Organics Limited Reports Loan Defaults Exceeding 30 Days on Bank Borrowings CI
17/03 Mangalam Drugs and Organics Limited Defaults on Loan Obligations to Bank of Maharashtra and Bank of Baroda CI
17/03 Mangalam Drugs and Organics Limited Defaults on Bank Loan Obligations Exceeding 30 Days with INR 70.705 Million to Bank of Maharashtra and INR 44.677 Million to Bank of Baroda CI
17/03 Mangalam Drugs and Organics defaults on loan obligations to Bank of Baroda, Bank of Maharashtra RE
06/02 Mangalam Drugs and Organics names Jeevan M. Dalvi as CFO RE
06/02 Mangalam Drugs and Organics Limited Approves the Appointment of Jeevan Mukund Dalvi as Chief Financial Officer, Effective February 6, 2026 CI
1 day+1.22%
1 week+1.82%
Current month+5.53%
1 month-11.03%
3 months+15.98%
6 months+5.60%
Current year+17.92%
1 week 30.5
Extreme 30.5
34.62
1 month 28
Extreme 28
36.46
Current year 25.7
Extreme 25.7
54.4
1 year 22.8
Extreme 22.8
73
3 years 22.8
Extreme 22.8
144.99
5 years 22.8
Extreme 22.8
173
10 years 20.65
Extreme 20.65
225.7
Manager TitleAgeSince
Chief Executive Officer 73 30/09/2011
Director of Finance/CFO - 06/02/2026
Compliance Officer 27 01/04/2026
Director TitleAgeSince
Chairman 73 02/02/2010
Director/Board Member 75 05/02/2015
Director/Board Member 38 28/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.22%+1.82% - - 53.01L
+3.97%+2.12%+49.43%+96.85% 1,04000Cr
+1.65%-2.55%+31.97%+59.89% 60TCr
+3.62%+4.56%+23.83%+92.72% 48TCr
+3.96%+3.23%+74.03%+41.54% 35TCr
+3.09%+3.03%+29.59%+47.09% 35TCr
+2.82%+2.20%+17.90%+40.67% 27TCr
+3.40%+0.99%-3.44%+12.10% 24TCr
+3.02%+3.06%+44.87%+48.39% 22TCr
+3.06%+3.50%+28.28%+91.91% 18TCr
Average +2.97%+2.38%+32.94%+59.02% 41.59TCr
Weighted average by Cap. +3.24%+2.31%+36.74%+67.88%

Financials

2025 2026
Net sales 317.58Cr 3.34Cr 3Cr 2.8Cr 2.54Cr 4.76Cr 4.79Cr 34Cr 13Cr 164.82Cr 13Cr 12Cr 530.12Cr 232.13Cr 2.44Cr 2.19Cr 2.05Cr 1.85Cr 3.48Cr 3.5Cr 25Cr 9.59Cr 120.48Cr 9.16Cr 8.96Cr 387.49Cr
Net income 6.72Cr 7L 6L 6L 5L 10.08L 10.15L 71.11L 27.77L 3.49Cr 26.51L 25.94L 11Cr -44Cr -46.66L -41.95L -39.15L -35.48L -66.61L -67.03L -4.7Cr -1.83Cr -23Cr -1.75Cr -1.71Cr -74Cr
Net Debt 94Cr 98.4L 88.47L 82.56L 74.83L 1.4Cr 1.41Cr 9.91Cr 3.87Cr 49Cr 3.69Cr 3.61Cr 156.31Cr 112.05Cr 1.18Cr 1.06Cr 98.79L 89.54L 1.68Cr 1.69Cr 12Cr 4.63Cr 58Cr 4.42Cr 4.32Cr 187.04Cr
Projected Income Statement - Annual - Mangalam Drugs & Organics Limited
Logo Mangalam Drugs & Organics Limited
Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemical products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed for research and development) is Bictegravir Na (IH).
Employees
319
Date Price Change Volume
14/26/14 ₹32.44 +1.22% 17,873
13/26/13 ₹32.05 +0.82% 16,833
12/26/12 ₹31.79 +2.35% 16,254
09/26/09 ₹31.06 -1.33% 1,81,357
08/26/08 ₹31.48 -4.87% 27,243